Opendata, web and dolomites

Oximonitor

The first portable monitoring medical device providing accurate prognosis for patients with circulatory failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oximonitor project word cloud

Explore the words cloud of the Oximonitor project. It provides you a very rough idea of what is the project "Oximonitor" about.

400    company    17    neonatal    microcirculatory    asphyxia    clinical    optical    effectiveness    75    expand    oximonitor    cells    clab    35    patented    membrane    2023    millions    body    financial    platform    o2    norwegian    societal    incorporates       learning    data    surface    dead    patient    care    ip    proof    health    life    sepsis    oxygenation    enormous    software    sufficient    symptom    accurately    sent    34    staff    odi    worldwide    patients    point    bedside    dashboard    decision    creates    likewise    medical    survivors    validated    specialists    recover    invasive    viability    report    function    machine    mlab    billion    start    extracorporeal    cagr    computing    22    costing    profit    collects    exemplified    collecting    generating    acute    ecmo    sublingually    inability    quantifying    hardware    monitoring    circulatory    cardiac    fingerprint    2017    first    treatment    poc    interpretation    heart    2022    count    market    cumulative    cloud    roi    conjunctiva    site    39    back    manner    individuals    respiratory    clinically    skin    12    monitors    predict   

Project "Oximonitor" data sheet

The following table provides information about the project.

Coordinator
ODI MEDICAL AS 

Organization address
address: OSLO SCIENCE PARK, GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website https://odimedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ODI MEDICAL AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Microcirculatory failure (the inability to deliver sufficient O2 to the cells of the body), is a symptom from several health conditions affecting millions of individuals worldwide (e.g. heart failure, neonatal asphyxia or sepsis). The societal and financial impact of these conditions is enormous, as exemplified by patients in need of cardiac and respiratory support (such as extracorporeal membrane oxygenation life support or ECMO), with only 17% of survivors, while costing up to 1.35 M€ for a 1-year treatment. Specialists cannot predict if these patients are clinically dead or can recover because available medical devices do not allow to monitoring patient´s microcirculatory function. To solve this, at ODI Medical (a Norwegian start-up company) we have developed OXIMONITOR, the first-ever proof-of-concept validated, patented and non-invasive point of care (POC) integrated platform used bedside that accurately monitors microcirculatory function by quantifying O2 delivery and allows to assess the effectiveness of the patient´s treatment of choice, all in a user-friendly manner. OXIMONITOR incorporates: (1) The mLab hardware which creates an “optical fingerprint” of the patient’s circulatory function by collecting data from the surface of the patient’s skin, the conjunctiva or even sublingually. (2) The cLab; a Cloud computing software based on machine learning technology that collects and analyses the data generating the patient´s interpretation report, which is sent back to the clinical site through a user-friendly dashboard for decision-making. The market of cardiac monitoring (our first clinical application) will reach €22 billion by 2022 at a CAGR of 3.9% (2017-2022). With OXIMONITOR we will contribute to the viability of our company, generating a cumulative profit of 34.39 M€ (ROI of 12.75) and growing our staff count 400% by 2023. Likewise, the IP generated by this project will allow us to expand the number of clinical applications using our platform.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIMONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIMONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More